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Traumatic brain injury (TBI) can induce intestinal inﬂammatory response and mucosal injury. Antioxidant transcription factor
nuclear factor erythroid 2-related factor 2 (Nrf2) has been shown in our previous studies to prevent oxidative stress and
inﬂammatory response in gut after TBI. The objective of this study was to test whether tert-butylhydroquinone (tBHQ), an Nrf2
inducer, can protect againstTBI-induced intestinal inﬂammatoryresponse andmucosalinjury in mice. Adult maleICR mice were
randomly divided into three groups: (1) sham + vehicle group, (2) TBI + vehicle group, and (3) TBI + tBHQ group (n = 12 per
group). Closed head injury was adopted using Hall’s weight-dropping method. Intestinal mucosa apoptosis and inﬂammatory-
related factors, such as nuclear factor kappa B (NF-κB), tumor necrosis factor-α (TNF-α), interleukin-1β (IL-1β), interleukin-
6 (IL-6) and intercellular adhesion molecule-1 (ICAM-1), were investigated at 24h after TBI. As a result, we found that oral
treatment with 1% tBHQ prior to TBI for one week markedly decreased NF-κB activation, inﬂammatory cytokines production,
andICAM-1expressioninthegut.AdministrationoftBHQalsosigniﬁcantlyattenuatedTBI-inducedintestinalmucosalapoptosis.
The results of the present study suggest that tBHQ administration could suppress the intestinal inﬂammation and reduce the
mucosaldamage following TBI.
1.Introduction
Traumatic brain injury (TBI) is known to cause several
secondary eﬀects, which lead to peripheral organs dys-
function. The close relationship between brain injury and
subsequent intestinal mucosal injury has been recognized
[1, 2]. This pathologic course may not only inﬂuence the
intestinal mucosa itself but also impair the remote organs,
leading to systemic inﬂammatory response syndrome (SIRS)
and multiple-organ dysfunction syndrome (MODS) [3].
Previous studies of our laboratory demonstrated that trau-
matic brain injury could lead to intestinal inﬂammatory
response mediated by increased nuclear factor kappa B (NF-
κB) and proinﬂammatory cytokines, which played a critical
roleinthepathogenesisofacutegutmucosalinjuryfollowing
TBI [4, 5]. Afterwards, using nuclear factor erythroid 2-
related factor 2 (Nrf2) knockout mice, we found that
Nrf2, which is the key transcription factor that mediates
the induction of cellular antioxidant defense mechanisms,
played an important protective role in limiting TBI-induced
intestinal inﬂammatory response and gut mucosal injury [6,
7]. However, it is not known whether activation of the factor
Nrf2 has a protective eﬀect in the intestinal inﬂammation
associated with TBI.
A wide range of natural and synthetic small molecules
with diverse chemical backgrounds have been shown to
induce the Nrf2 activity; tert-butylhydroquione (tBHQ) is
the major one that exerts powerful antioxidant potential [8–
10]. It has been documented that tBHQ protects the animals
and cell lines against acute toxicity and oxidative insult,2 Mediators of Inﬂammation
presumably through the induction of many cytoprotective
and detoxifying enzymes such as epoxide hydrolase [11],
glutathione-S-transferase [12], and glucoronyltransferase
[13]. This activation is dependent on the translocation of
Nrf2 from the cytoplasm to the nucleus through inducer
interaction with Keap1, the cytoplasmic repressor of Nrf2
[14]. Nevertheless till now, no study was found in the
literatureto address thetherapeuticeﬀectof theactivation of
Nrf2 by tBHQ on the TBI-induced intestinal inﬂammatory
response. The purpose of the current study was therefore to
determine the inﬂuence of tBHQ administration on intesti-
nal NF-κB activity, proinﬂammatory cytokines expression,
and apoptosis after TBI.
2.Materialsand Methods
2.1. Animals. All procedures were approved by the Institu-
tional Animal Care Committee and were in accordance with
the guidelinesof the National Institutesof Health on the care
and use of animals. Age- and weight-matched adult male
ICR mice (6–8 weeks, 28–32g) were purchased from Animal
Center of Chinese Academy of Sciences, Shanghai, China.
Micewere housed at 23 ±1◦Cinhumidity-controlledanimal
quarters with 12-hour light/dark cycle.
2.2. Experimental Protocol. The experimental groups con-
sisted of sham + vehicle group, TBI + vehicle group, and
TBI + tBHQ group (n = 12 per group). Mice of TBI +
tBHQ group were fed the tBHQ-supplemented diet for one
week prior to injury, but mice of sham + vehicle group and
TBI + vehicle group were given the control food. For tBHQ
feeding, food pellets were powdered in a coﬀee grinder and
dry mixed with 1% tBHQ (w/w). Distilled water was added
to the powder (equal v/w), thoroughly mixed, and reshaped
into food pellets. The pellets were then baked at 60◦Cf o r3h .
Control food was processed in the same manner without the
addition of tBHQ [15]. This dose and medication of tBHQ
administration have been widely used in analogous animal
models described elsewhere [15, 16].
The mouse model of TBI was employed as described
[17] being previously developedin ourlaboratory [18]. Mice
were anesthetized by intraperitoneal injection with sodium
pentobarbital (50mg/kg). A round, ﬂat, and 6mm diameter
Teﬂon impounder was centered between the ears and eyes.
TBI was induced by a 100g weight dropped from a 12cm
height along a stainless steel string, which translated into
1200g/cm. This model is generally associated with 20%
mortality within the ﬁrst 5min after injury, and no delayer
mortality was observed thereafter [18]. Sham mice were
subjected to identical treatment with the exception that no
injury was performed.
Animals were decapitated at 24h following sham or
injury for sample collection. Six mice in each group
were sacriﬁced for electrophoretic mobility shift assay
(EMSA) and enzyme-linked immunosorbent assay (ELISA),
the others were for immunohistochemistry and termi-
nal deoxynucleotidyl transferase-mediated dUTP nick end
labeling (TUNEL) study. For EMSA and ELISA analysis,
mice were exsanguinated by cardiac puncture, and a 3-cm
segment of the jejunum 8cm distal to Treitz ligament was
rapidly removed and stored at liquid nitrogen immediately.
For immunohistochemistry and TUNEL study, mice were
perfused via left ventricular puncture with cold saline (4◦C),
followedby4%neutralbuﬀeredformalin.The3-cmsegment
of the jejunum was taken, stored overnight in 4% neutral
buﬀered formalin, and then embedded in paraﬃn.
2.3. Nuclear Protein Extract and EMSA. The DNA binding
activity of NF-κB in intestine was determined by EMSA.
Nuclear protein of intestinal tissue was extracted and quan-
tiﬁed as described previously in [6]. EMSA was performed
using a commercial kit (Gel Shift Assay System; Promega,
Madison, WI) following the methods in our laboratory.
A Consensus oligonucleotide probe for NF-κB( 5  -AGT
TGA GGG GAC TTT CCC AGG C-3 ) was end-labeled
with [γ-32P]-ATP (Free Biotech., Beijing, China) with T4-
polynucleotide kinase. EMSA was performed according to
our previous study [6]. NF-κB activity was quantiﬁed by
computer-assisted densitometric analysis.
2.4. ELISA Analysis. The intestinal levels of inﬂamma-
tory cytokines such as tumor necrosis factor-α (TNF-
α), interleukin-1β (IL-1β), and interleukin-6 (IL-6) were
quantiﬁed using ELISA kits speciﬁc for mouse according
to the manufacturers’ instructions (TNF-α from Diaclone
Research, France; IL-1β, IL-6 from Biosource Europe SA,
Belgium) and our previous study [6]. The cytokine contents
in the intestinal tissue were expressed as pg per milligram
protein.
2.5. Immunohistochemical Staining. The paraﬃn-embedded
sections (4μm) were used for Immunohistochemical assay,
which was performed with a goat antimouse intercellular
adhesion molecule-1 (ICAM-1) antibody (diluted 1:200,
R&D Systems, Inc., Minnesota, USA), according to our pre-
vious study [6]. Microscopy of the immunohistochemically
stained tissue sections was performed by an experienced
pathologist blinded to the experimental condition. Evalua-
tion of sections was undertaken by assessing the intensity of
staining (5 grades). “0” indicates no detectable positive cell;
“1” indicates very low density of positive cells, “2” indicates
a moderate density of positive cells, “3” indicates the higher,
but not maximal density of positive cells, and “4” indicates
the highest density of positive cells.
2.6. TUNEL Study. The paraﬃn-embedded sections were
also detected for apoptotic cells by TUNEL method. The
procedures were according to instruction of the kit (ISCDD,
Boehringer Mannheim, Germany) and our laboratory meth-
ods [7]. Ten villi and crypts of each section were observed
under a light microscope, and the average number of
TUNEL-positive cells in 100 counted cells was assigned as
the apoptotic index. The distinctive morphological features
of apoptosis were used to recognize apoptotic cells. Small
clusters of dead cell fragments were assessed as originatingMediators of Inﬂammation 3
from one cell and given a single count,and any doubtfulcells
were disregarded.
2.7. Statistical Analysis. Software SPSS 13.0 was used for
the statistical analysis. All data were expressed as mean ±
SEM.Themeasurementsweresubjectedtoone-wayANOVA.
Diﬀerences between experimental groups were determined
byFisher’s LSDposttest. Signiﬁcancewasassigned atP<. 05.
3.Results
3.1. EMSA for NF-κB. As shown in Figure 1, low intestinal
NF-κB binding activity (weak EMSA autoradiography) was
detected in the sham + vehicle group. Compared with sham
+ vehicle group, NF-κB binding activity in the intestinal
tissue was signiﬁcantly increased in TBI + vehicle group. In
TBI + tBHQ group, the intestinal Nrf2 binding activity was
signiﬁcantly downregulated after TBI. The results showed
that tBHQ treatment could markedly suppress the activation
of NF-κB in the gut following TBI.
3.2. ELISA for Inﬂammatory Cytokines. Concentrations of
inﬂammatory cytokines including TNF-α,I L - 1 β,a n dI L -
6 were low in the mice gut of sham + vehicle group, as
shown in Figure 2. Compared with sham + vehicle group,
intestinal levels of TNF-α,I L - 1 β,a n dI L - 6w e r eg r e a t l y
induced in TBI + vehicle group. tBHQ administration after
TBI could lead to signiﬁcantly decreased TNF-α,I L - 1 β,a n d
IL-6 concentrations in mice intestinal tissue.
3.3. Immunohistochemistry for ICAM-1. The immunohis-
tochemical assay showed low ICAM-1 immunoreactivity
in the villous interstitium and lamina propria in sham +
vehicle group; see Figure 3.C o m p a r e dt ot h es h a m+v e h i c l e
group, ICAM-1 in the intestinal tissue was signiﬁcantly
upregulated in TBI + vehicle group. In TBI + tBHQ group,
the level of ICAM-1 immunoreactivity was signiﬁcantly
decreased. The results suggested that tBHQ administration
could signiﬁcantly down-regulate the ICAM-1 expression in
mice gut following TBI.
3.4. TUNEL for Intestinal Mucosal Apoptosis. Low apoptotic
index was found in the sham + vehicle group mice intestinal
tissue, as shown in Figure 4. In TBI + vehicle group, the
apoptotic index in the studied mice gut was found to be
signiﬁcantly increased compared with that in sham + vehicle
group animals. In TBI + tBHQ group, the apoptotic index in
the intestinal tissue was signiﬁcantly decreased. The results
suggested that tBHQ treatment could inhibit apoptotic cell
death in the intestine and could potentially reduce the
mucosal injury following TBI.
4.Discussion
This study revealed that the inﬂammatory-related factors
including NF-κB, proinﬂammatory cytokines, and ICAM-
1 in the intestine were signiﬁcantly upregulated following







































Figure 1: NF-κB binding activity in the intestinal tissue in sham +
vehiclegroup, TBI +vehiclegroup, andTBI+tBHQ group (n = 6).
EMSA autoradiography of NF-κBD N Ab i n d i n gi ss h o w no nt o p
of the graph, and the order of individual bands corresponds to
that of graph bars. Lane 1: sham + vehicle group; lane 2: TBI +
vehiclegroup; lane3:TBI+tBHQgroup. tBHQtreatment markedly
suppressed the activation of NF-κB in the gut followingTBI.
∗∗P <
.01 versus sham + vehicle group; ##P <. 01 versus TBI + vehicle
group.
At the same time, treatment with tBHQ markedly reduced
TBI-induced apoptotic cell death in the intestine. These
ﬁndings reported here suggest for the ﬁrst time that tBHQ
administration can suppress the intestinal inﬂammation and
reduce the mucosal injury following TBI.
To defend against exogenous toxins and injury, cells
possess a large number of cytoprotective and detoxifying
enzymes whose expression is rapidly increased in response
to insults. Many of these genes contain a common promoter
element called the antioxidant response element (ARE).
Several transcription factors can bind to ARE; however,
Nrf2 is the major one that binds to and activates the
expression of these ARE-mediated gene products [19–21].
In recent researches, the central role of Nrf2 in cell survival
has been well eatablished in vitro and in vivo [22, 23].
Importantly,numerouslinesevidencegeneratedintherecent
years have implied the anti-inﬂammatory eﬀect of Nrf2 in
a variety of experimental models [24–27]. Our previous
studies showed that in response to TBI, mice lacking Nrf2
exhibited increased intestinal inﬂammatory response and
mucosal injury [6, 7]. These provide the evidence that
Nrf2 plays an important role in the gut injury after TBI.
Upregulation of Nrf2 may bring great beneﬁt to the TBI-















































































Figure 2: Concentrations of inﬂammatory cytokines in the intestinal tissue in sham + vehicle group, TBI + vehicle group, and TBI + tBHQ
group (n = 6). The ﬁgure indicates that concentrations of TNF-α,I L - 1 β, and IL-6 in the intestine were signiﬁcantly increased after TBI and
could be suppressed when treated with tBHQ.











































Figure 3: Expression of ICAM-1 in the intestinal tissue in sham + vehicle group, TBI + vehicle group, and TBI + tBHQ group (n = 6). (a)
Sham+ vehicle group mice showinglow ICAM-1 immunoreactivity. (b) TBI + vehicle group showing increased ICAM-1 immunoreactivity.
(c) TBI + tBHQ group mice showing less ICAM-1 immunoreactivity than those of TBI + vehicle group. (d) tBHQ administration
signiﬁcantlydownregulated the ICAM-1 expression in mice gut followingTBI.
∗∗P <. 01versus sham + vehicle group; ##P <. 01 versus TBI
+v e h i c l eg r o u p .
Synthetic phenolic antioxidant tBHQ used widely as
a food-additive antioxidant for humans has long been of
interest as eﬀective inducer of Nrf2 [14, 28, 29]. There
is abundant evidence that tBHQ treatment increases Nrf2
activation and confers protection [14, 30]. In vitro studies
have shown that, as a result of its action on Nrf2, tBHQ
is eﬀective in inducing ARE-dependent gene expression in
cultured astrogytes and protecting neurons from oxidative
injury [31]. Other in vivo studies have shown that the
neuroprotective eﬀect of tBHQ on oxidative stress and
ischemic injury is lost in Nrf2-deﬁcient mice [14, 15].
Additionally, the majority of tBHQ-induced genes in glia
and neurons have been shown to be dependent on Nrf2 by
































Figure 4: TUNEL immunohistochemistry staining in the intestinal tissue in sham + vehicle group, TBI + vehicle group, and TBI + tBHQ
group (n = 6). (a) sham + vehicle group mice showing few TUNEL positive cells (stained brown); (b) TBI + vehicle group mice showing
more TUNEL positive cells; (c) TBI + tBHQ group mice showing less TUNEL positive cells than TBI + vehicle group; (d) tBHQ treatment
signiﬁcantly decreased the apoptotic index in the intestinal tissue following TBI.
∗∗P <. 01 versus sham + vehicle group; ##P <. 01 versus
T B I+v e h i c l eg r o u p .
above,wehypothesizethatactivationofNrf2withtBHQmay
represent an attractive target for combating TBI-induced
intestinal inﬂammatory response and mucosal injury.
The intestinal inﬂammatory response following trauma
is characterized by intestinal recruitments of neutrophils
and monocytes through activation of NF-κB, releasing
many inﬂammatory cytokines,and upregulationof adhesion
molecule, which has been implicated in the pathogenesis of
TBI-induced gastrointestinal dysfunction [4]. NF-κBi so n e
of the most important proinﬂammatory modulators, which
can be activated by lesion-induced oxidative stress, bacterial
endotoxin, or cytokines and subsequently transactivate the
expression of many cytokines and adhesion molecules [32].
Proinﬂammatory cytokines, including interleukins (ILs) and
TNF-αreleasedearlyafteraninﬂammatory stimulus,canini-
tiate the inﬁltration of inﬂammatory cells into the intestine
by activating ICAM-1 and other adhesion molecules [33].
NF-κB activation enhances the transcription of proinﬂam-
matory cytokines, and the cytokines are known to in turn
activate NF-κB[ 34]. The positive feedback is believed to
serve to amplify inﬂammatory signals and exacerbate tissue
injury. Our study showed that at 24h after TBI, upregulation
ofNF-κB,TNF-α,IL-1β,andIL-6wasevidentintheintestine
and could be inhibited when treated with tBHQ. These
results illustrated that tBHQ administration could suppress
the intestinal inﬂammation following TBI.
The major changes of gastrointestinal function after
TBI can be summarized into four aspects: gastrointestinal
mucosa ischemia, gut motility dysfunction, disruption of
gut barrier, and alteration of intestinal mucosal absorptive
function. Apoptosisis an important factor in gastrointestinal
physiological cell renewal, which can be triggered by noxious
stimuli such as trauma and ischemia [35, 36]. Previous stud-
ies of our laboratory deﬁnitely demonstrated that marked
apoptosis of the intestinal epithelial cells occurred after TBI,
and it was supposed to play an important role in the gut
barrier damage and increased permeability of the intestinal
epithelium, leading to possible translocation of intraluminal
microbes and bacterial toxins [5, 6]. However, there is still
no eﬀective treatment for the gut mucosa injury caused
by TBI. In the present study, we found that at 24h after
TBI, increased intestinal mucosal apoptosis was evident and
could be suppressed by tBHQ administration. These results
suggested that tBHQ could aﬀord protection to the TBI-
induced gut mucosal damage.
Although the precise mechanism regarding the anti-
inﬂammatory ability of tBHQ remains elusive, several lines
of evidence indicate that Nrf2 and NF-κB signaling pathways6 Mediators of Inﬂammation
contribute to the pathophysiological process. The prevailing
theory is that Nrf2 interferes with inﬂammatory signal-
ing pathways by inhibiting NF-κBa c t i v a t i o nt h r o u g ht h e
maintenance of cellular redox status. Oxidative stress from
reactive oxygen species (ROS) is believed to be involved in
the progression of gastrointestinal dysfunction secondary to
TBI[37].ActivationoftheNF-κBsignalingpathwayhasbeen
sho wnt ober esponsi v et oe x c essR OSandisimportantinthe
generation of inﬂammation [26]. The antioxidant transcrip-
tion factor Nrf2 has been shown to play an important role in
limiting ROS levels and thereby aﬀect redox-sensitive NF-κB
signaling pathway involved in the inﬂammation [19, 38]. It
is therefore implied that tBHQ may play an important role
in anti-inﬂammation by a mechanism of the augmentation
of cellular antioxidative system via upregulation of Nrf2
signaling pathway resulting in decreased pro-inﬂammatory
cytokines production and adhesion molecules expression
via inactivation of NF-κB signaling pathway. It is assured
that further ingenious researches are needed and will be
conducted in our laboratory.
In summary, the results showed that oral treatment with
tBHQ prior to TBI markedly decreased NF-κBa c t i v a t i o n ,
inﬂammatory cytokinesproduction,andICAM-1expression
in the gut. Additionally, tBHQ administration signiﬁcantly
attenuated TBI-induced intestinal mucosal apoptosis. These
results suggest that tBHQ maybe an eﬀective therapeutic
drug for the treatment of TBI-induced gut injury with
a potential mechanism of upregulation of Nrf2 signaling
pathway.
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